ASX Announcements

Patent to 2034 granted in Europe for Neuren's NNZ-2591
Phase 3 trial of trofinetide in Rett syndrome commences
Neuren Corporate Presentation, October 2019
Appendix 4C - quarterly
FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes
Pause in Trading
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
Neuren approaching key milestones in Q4 2019
Neuren advances pipeline for neurodevelopmental disorders
Half Yearly Report and Accounts

1 2 3 4 5 6 7 8 9 10 ... Next